Combination chemotherapy and immunotherapy in metastatic non-small cell lung cancer: a setback for personalized medicine?

The management landscape for metastatic non-small cell lung cancer (NSCLC) has changed considerably beyond chemotherapy alone. This is due to the introduction of targeted therapies for patients with targetable mutations and the advent of immune checkpoint inhibitors.